Axicabtagene ciloleucel (Yescarta) — Clinical FAQs

Question 1

What is Axicabtagene ciloleucel FDA-approved to treat?

Accepted Answer

Axicabtagene ciloleucel is FDA-approved for the following oncology indications: 1. Relapsed or refractory large B-cell lymphoma (DLBCL, PMBCL, high-grade B-cell lymphoma, DLBCL from follicular lymphoma) after two or more lines of systemic therapy in adults (FDA approved October 2017) 2. Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy in adults (FDA approved September 2022) 3. Relapsed or refractory large B-cell lymphoma in adults who have not responded to or relapsed within 12 months of first-line chemoimmunotherapy (second-line setting; FDA approved April 2022).

Question 2

How does Axicabtagene ciloleucel work (mechanism of action)?

Accepted Answer

Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed CAR-T cell therapy utilizing a retroviral vector to express a second-generation CAR with an anti-CD19 FMC63 scFv, CD28 transmembrane and costimulatory domain, and CD3ζ signaling domain. The CD28 costimulatory domain drives rapid and robust early expansion compared to 4-1BB-based constructs. Infused CAR-T cells bind CD19 on malignant B cells leading to activation, proliferation, and targeted cytolysis. Lymphodepletion conditioning enhances homeostatic expansion and reduces regulatory T-cell competition. Higher peak expansion may contribute to both efficacy and the historically higher rate of severe CRS and neurotoxicity observed compared to 4-1BB constructs.

Question 3

How is Axicabtagene ciloleucel administered?

Accepted Answer

Axicabtagene ciloleucel is administered Intravenous (IV). Single IV infusion at a REMS-certified center after lymphodepletion with fludarabine 30 mg/m²/day IV × 3 days and cyclophosphamide 500 mg/m²/day IV × 3 days, completed 2–7 days before infusion.

Question 4

What are the most common side effects of Axicabtagene ciloleucel?

Accepted Answer

The most commonly reported side effects of Axicabtagene ciloleucel (≥10% incidence) include: CRS (any grade, >90%), Pyrexia, Hypotension, Tachycardia, Fatigue and others (10 total). Consult your oncologist for complete prescribing information.

Question 5

Does Axicabtagene ciloleucel have a black box warning?

Accepted Answer

Yes. Axicabtagene ciloleucel carries FDA black box warning(s) regarding: 1. Cytokine release syndrome (CRS): severe or life-threatening; historically higher rates of Grade 3+ CRS compared to 4-1BB-based constructs 2. Immune effector cell-associated neurotoxicity syndrome (ICANS): including fatal encephalopathy and cerebral edema 3. Available only through the YESCARTA REMS Program

Question 6

Is Axicabtagene ciloleucel safe during pregnancy?

Accepted Answer

Axicabtagene ciloleucel pregnancy safety: No adequate human data; presumed fetal risk based on mechanism. Effective contraception required for at least 6 months post-infusion. Unknown breast milk excretion.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

axicabtagene ciloleucel — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms